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                                   INTRODUCTION
Rheumatic heart  disease  plays a major  debilitating role  in Indian population 
causing  high  morbidity  and mortality,  affecting   the  population in  their  productive 
phase of life. It impairs the quality of life and leads to   psycho-social and economic 
burden to their  family  and the society. With the clinical introduction of cardiac valvular 
prosthesis  in  1960,  valve  replacement  has  saved   a  number  of   lives   affected  by 
hemodynamically significant  valvular disease. However, prosthetic valve replacement 
is   not   with  out  danger  and  it   became evident  that  "valve  replacement  is  simply 
exchanging one disease for another"(1). In spite of tremendous strides toward perfecting 
materials and design, the ideal valve remains elusive.  Thromboembolism continues to 
be a major cause of morbidity and mortality in patients who have undergone mechanical 
valve replacement.  Recent surgical trend in treating  Rheumatic  mitral  valve disease  is 
to Repair the valve. If  Repair  is not feasible, then valve replacement is still undertaken 
knowing the  complications unique  to prosthetic  valve replacement  in the interest of 
saving the life.
ANATOMY OF MITRAL VALVE
The  Mitral  valve   apparatus  consists  of  leaflets,  annulus,  chordae tendineae, 
papillary muscles, and left ventricle. Mitral valve and its apparatus plays an important 
role in maintaining the  left ventricular geometry and function..
Annulus:-
The Mitral  annulus  is  the area  of  leaflet  attachment  to  muscular fibers  of  the 
atrium and  ventricle.  The  annulus  is  pliable,  permitting  sphinteric  contraction   and 
decreases  in  diameter  during  each  systolic  contraction  by approximately  26%.  The 
orifice of the Mitral valve also changes shape, from elliptical during ventricular systole 
to circular during late diastole. This flexibility increases leaflet coaptation during systole 
and maximizes orifice area during diastole. Changes in size and shape of the annulus 
result from relaxation and contraction of the basoconstrictor muscles (bulbospiral and 
sinospiral bundles). In the horizontal plane the annulus is saddle-shaped. Anteriorly, the 
annulus  is  attached  to  the  fibrous skeleton  of  the  heart,  extending between  the  two 
fibrous  trigones.  This  limits  its  pliability  and  its capacity  to  dilate  with  mitral 
regurgitation (MR). The posterior annulus is more flexible and is not attached to rigid 
surrounding structures. This is confirmed by  the clinical observation that dilation of the 
annulus occurs posteriorly with MR. 
Anatomical knowledge of the mitral annulus and surrounding structures is critical 
to avoid inadvertent damage during mitral surgery. The circumflex coronary artery runs 
laterally around the mitral annulus in the posterior atrioventricular groove. The coronary 
sinus runs more medially in the same groove. The artery to the atrioventricular node, 
usually a branch of the right coronary artery, runs parallel and close to the annulus of the 
anterior leaflet near the posteromedial commissure. The aortic valve is situated between 
the anterior and posterior fibrous trigones. The bundle of His is located near the posterior 
trigone. 
Leaflets:-
The  mitral  valve  has  two  leaflets,  the  anterior  (aortic)  and posterior  (mural) 
leaflets.  The leaflets are attached   to the mitral annulus and at  its free border to the 
papillary muscles by primary and secondary chordae. The anterior mitral leaflet is in 
direct continuity with the fibrous skeleton of the heart. This leaflet is contiguous with the 
left and noncoronary cusps of the aortic valve and the area below the intervening aortic 
commissure, termed the fibrous subaortic curtain. Although the anterior leaflet occupies 
only 35% to 45% of the annular circumference, its leaflet area is almost identical to that 
of the posterior leaflet. 
The posterior leaflet is rectangular. The free margin of the posterior leaflet has 
two  clefts  that divide  the  posterior  leaflet  into  three  scallops:  the  largest or  middle 
scallop,  the  posteromedial  scallop,  and the anterolateral scallop.  Fan-shaped chordae 
insert into and define the clefts between the individual posterior scallops. Motion of the 
posterior leaflet is more restricted than that of the anterior leaflet; however, both mitral 
leaflets contribute importantly to effective valve closure.  The  valvular surface area is 
bigger  compared  to  the  orifice  area.  The  ratio  is  close  to  2:1.  This   difference 
exaggerates  even  more during systole because of  the  sphincter  action of   annulus 
which reduces further the orifice area.
There are  three phases in valve orifice closure.
1) Edge to edge meeting between leaflet.
2) Upward bulge of leaflet.
3) Final phase maximal cooptation of leaflet almost they lie vertically. 
The surface of the mitral leaflet is divided into three zones corresponding to areas 
of chordal insertion and leaflet coaptation. The rough zone is the leading edge of the 
anterior and posterior mitral leaflets. This zone is the contact surface of the mitral leaflets 
during systole. The clear zone is peripheral to the rough zone and represents most of the 
body  of  the  leaflet;  this portion  of  the  mitral  valve  billows  into  the  atrium during 
ventricular contraction. The basal zone, between the clear zone and the annulus, receives 
the insertion of the basal chordae tendineae (tertiary chordae), which originate directly 
from the trabeculae of the left ventricle. The basal zone is found only on the posterior 
leaflet. 
Chordae Tendineae :-
The chordae tendineae are chords of fibrous tissue that attach the mitral leaflets to 
either the papillary muscles or the left ventricular free wall. They often subdivide and 
interconnect before they attach to the leaflets. The chordae are divided into primary , 
secondary ,  and tertiary chordae. Primary chordae attach directly to the fibrous band 
running  along  the  free  edge  of  the  leaflets.  These  chordae  ensure that  the  contact 
surfaces (rough zone) of the leaflets coapt without leaflet prolapse or flail. Secondary 
chordae attach to the ventricular surface of the leaflets at the junction between the rough 
and clear zones. These chordae contribute to ventricular function. Secondary chordae 
helps  the  ventricle  to  contract in  an  efficient  cone-shaped  fashion;  when  secondary 
chordae are excised, the left ventricle assumes a globular shape. Tertiary chordae are 
unique to the posterior leaflet. They arise as strands directly from the left ventricular 
wall or from small trabeculae to insert into the ventricular surface of the leaflet near the 
annulus. 
Papillary Muscles :-
The  anterolateral  and  posteromedial  papillary  muscles  each  supply chordae 
tendineae to both leaflets. The two groups of papillary muscles support the anterolateral 
and posteromedial commissures and arise from the junction of the apical and middle 
thirds of the ventricular wall. The anterolateral papillary muscle receives a dual blood 
supply from the anterior descending coronary artery and either a diagonal branch or a 
marginal  branch  of the  left  circumflex  artery.  The  posteromedial  papillary muscle 
receives its blood supply from either the left circumflex artery or a distal branch of the 
right coronary artery. Because of the single blood supply to the posteromedial papillary 
muscle, infarction of the posteromedial papillary muscle is much more common. Blood 
supply  comes  through  a  large  central  artery  at  its  base  from epicardial  vessel  then 
dividing in to network  to supply the papillary muscle. The occlusion of large central 
artery severely damages  the entire papillary muscle, due to lack  of collateral supply and 
leading to necrosis of the papillary muscle which    leads to mitral regurgitation.
Left Ventricle :-
The posterior left ventricular wall and papillary muscles play an important role in 
leaflet coaptation and valve competence. Papillary muscles are aligned parallel to the 
ventricular wall and attach via chordae to the free edges of the valve leaflets. These 
muscles project from the trabeculae and may be single, bifid, or a row of muscles arising 
from the ventricular wall. During isovolumetric contraction the mitral leaflets are pulled 
downward  and  together  by  this  interaction.  Ventricular  dilatation may  affect  the 
alignment and tension on the papillary muscles and valve competence.
Atrial Fibrillation :- 
This   is  the  Commonest  rhythm disturbance  that   accompanies   mitral  valve 
disease. In Atrial fibrillation  walls of the  atria  shudder  fast  and atrial contraction  will 
not be present.  At the same time ventricular rate is fast and irregular due to chaotic 
bombardment of AV node by more than 700 impulse per minute from the atria. The 
trigger of  an AF is  a focus of  acute localized wall stretch,  which when on chronic 
remodeling occurs with histological changes. Occurrence of AF has been consistently 
related to the size of the left atrium. Univariate analysis in  one study revealed that the 
incidence of AF was 3% when the left atrial diameter was less than 4.0 cm but increased 
to 54%  if the left atrial diameter was more than 4.0 cm, thus explaining the highest 
incidence  in  patients  with  mitral  valve  disease,  which  causes   maximum left  atrial 
enlargement.(2)
 For AF patients, SA node histology indicates severe degeneration of normal pacemaker 
tissue(3) 
It is postulated that fibrosis and degeneration of the atrial myocardium in valvular 
heart disease, especially of rheumatic etiology disturbs impulse propagation in the atria 
and leads to AF(4)
Atrial fibrosis  probably contributes to persistent AF after valvuloplasty  or valve 
replacement/repair. In patients with valvular  disease, AF also occurs more frequently 
with mitral valve  calcification,  mitral valve prolapse and following valve replacement 
surgery.(5,6)
 Atrial wall shows myofibrillar changes with increased fibrous tissue deposition, 
leading  to  haphazard  electrical  activity.  Mechanically  there  is  a  loss  of  atrial 
contribution to stroke volume by up to 30%.  Combination of loss of atrial kick and fast 
ventricular rate ( loss of diastolic  filling time) occur  plus loss of  normal presystolic 
closure timing of atrioventricular valves   due to fast ventricular rate and absent atrial 
contraction, all of which  decreases  cardiac output and mitral regurgitation may occur.
Dilatation of atrial wall leads to increased secretion of Atrial natriuretic peptide. 
Fast  heart  rate  precipitates  congestive  cardiac  failure  by  tachycardia  mediated 
cardiomyopathy  (7)  there  by  AF  per  se   is  responsible  for  overt  heart  failure  by 
increasing myocardial metabolism by provoking rapid myocardial contraction leading to 
exhaustion. Dilated atrium, loss of atrial contraction are factors for clot formation. After 
the onset  of AF, stroke is the  most feared and calamitous complication. Compared to 
sinus rhythm AF  carries an increased mortality of about 1.5- 1.9  independent of heart 
disease and age and part of this increased mortality is likely due to stroke in its various 
presentation.(8,9)
Evidence based Treatment
The Committee on Management of Patients with Valvular Disease was given the 
task of reviewing and compiling this information base and making recommendations for 
diagnostic testing, treatment, and physical activity. These guidelines follow the format 
established in previous American College of Cardiology/American Heart Association 
(ACC/AHA)  guidelines  for  classifying  indications  for  diagnostic  and  therapeutic 
procedures :
Class I :  Conditions for which there is evidence and / or general agreement that a 
given procedure or treatment is useful and effective.
Class II : Conditions for which there is conflicting evidence and/or a divergence of 
opinion  about  the  usefulness/efficacy  of  a  procedure  or  treatment  IIa. 
Weight of evidence/opinion is in favour or usefulness/efficacy 
IIb. Usefulness/efficacy is less well established by evidence/opinion.
Class III : Conditions for which  there is evidence and/or general agreement that the 
procedure/treatment is not useful and in some cases may be harmful.
Indication for Mitral Valve Replacement
Indications for valve replacement pertain to those types of valve  that are unlikely 
to be repaired or which have been shown to have poor long-term success after previous 
intervention. 
Mitral Stenosis
Mitral stenosis is almost exclusively caused by rheumatic fever. The pathologic 
changes  in  rheumatic  valvulitis  are  mainly  fusion of  the  valve  leaflets  at  the 
commissures;  shortening  and  fusion of  the  chordae  tendinae;  and  thickening  of  the 
leaflets due to fibrosis,  contraction, and calcification. 
Stenosis usually develops one or two decades after the acute illness of rheumatic fever 
with no or slow onset of symptoms until the stenosis becomes more severe. Limitation of 
exercise tolerance is usually the first symptom followed by dyspnea that can progress to 
pulmonary  edema.  New  onset  atrial  fibrillation and  risk  for  thromboembolism, 
hemoptysis, and pulmonary hypertension are other common symptoms in patients with 
mitral stenosis. 
The diagnostic  workup of  the symptomatic  patient  with mitral stenosis  should 
include  a  complete  cardiac  catheterization, including  coronary  angiography  in  any 
patient over the age of 40. Under the age of  40, echocardiographic findings of the mitral 
valve  is  enough    in  most  symptomatic  patients  for  the  definition  of  mitral valve 
pathology unless there is a history of chest pain or coronary artery disease. 
In general, operation is prescribed when the mean valve area is 1.0 cm2 or less 
(normal mitral valve area: 4–6 cm2 - however, with a "mixed" lesion of mitral stenosis 
and mitral regurgitation, the valve area in symptomatic patients occasionally may be as 
large as 1.5 cm2. Asymptomatic patients are generally not considered for surgery but it is 
in  the  asymptomatic  patients  with  significant  hemodynamic  mitral stensosis  ,  still 
surgery is considered. 
ACC / AHA RECOMMENDATIONS FOR MITRAL VALVE REPLACEMENT 
IN MITRAL STENOSIS
1. Patients with moderate or severe MS (mitral valve area ≤1.5cm2) and NYHA 
functional  Class  III-IV  symptoms  who  are  not  considered  candidates  for 
percutaneous balloon valvotomy or mitral valve repair – Class I
2. Patients with severe MS (mitral valve area  ≤ 1 cm2) and severe pulmonary 
hypertension  (pulmonary  artery  systolic  pressure  >  60  to  80mm Hg)  with 
NYHA functional Class I-II symptoms who are not considered  candidates for 
percutaneous balloon valvotomy or mitral valve repair – Class IIa.
Mitral Regurgitation
The  etiology  of  mitral  regurgitation  is  very  diverse.  Except in  cases  of  acute 
ischemic  mitral  regurgitation  and  endocarditis, where  indications  are  more 
straightforward, indication generally for regurgitative lesion are complex. Etiology  of 
regurgitation are degenerative (mitral prolapse, ruptured/elongated chordae), rheumatic, 
infectious, and ischemic diseases of the mitral valve. Most of these are now amenable to 
mitral valve repair and reconstruction .
For  any  of  the  preceding  major  pathologic  subsets,  indications for  surgery  in 
patients with mitral regurgitation vary from the asymptomatic patient with an enlarging 
but  well   functioning left  ventricle  and atrium to severely  depressed  left  ventricular 
function.  Any  symptomatic  patient  with  significant  mitral  regurgitation (3+  to  4+) 
should be operated on, and operation should be considered in any relatively symptom-
free  individual  if  there  is  objective evidence  of  left  ventricular  deterioration  and 
significant increase in left ventricular end-systolic and end-diastolic volumes.
Regurgitation  through  the  valve  is  usually  measured  with  Doppler 
echocardiography,  but  MRI  is  another  noninvasive  technology for  measuring  the 
regurgitant  flow  and  can  provide  measurements of  ventricular  end-diastolic/systolic 
volumes and ventricular mass. Left ventricular angiography with coronary angiogram 
can  be  helpful  but  is  otherwise indicated  for  evaluating  the  coronary  arteries 
preoperatively in patients older than 40 years. 
It is important to stress that ejection fraction is a poor indicator of left ventricular 
function  in  patients  with  mitral  regurgitation. Depressed  cardiac  output  (<  40%) 
therefore usually indicates severe left ventricular dysfunction, and results of surgery are 
not  as  favorable  in  these  patients  as  they  are in  patients  with  normal  ventricles. 
Compared to ejection fraction, measurements of end-systolic volume and diameter are 
more  reliable noninvasive  parameters  to  evaluate  the  status  of  the  left  ventricle and 
determine the optimal time for operation .
ACC / AHA RECOMMENDATIONS FOR MITRAL VALVE SURGERY IN 
NONISCHEMIC SEVERE MITRAL REGURGITATION.
1. Acute symptomatic MR in which repair is likely – Class I
2. Patients with NYHA functional Class I, III, or IV symptoms with normal LV 
function defined as ejection fraction > 0.60 and end-systolic dimension < 45 
mm – Class I.
3. Symptomatic or asymptomatic patients with mild LV dyfunction, ejection 
fraction 0.50 to 0.60, and end-systolic dimension 45 to 50 mm – Class I. 
4. Symptomatic or asymptomatic patients with moderate LV dysfunction, 
ejection fraction 0.30 to 0.50, and/or end-systolic dimension 50 to 55 mm – 
Class 1.
5. Asymptomatic patients with preserved LV function and atrial fibrillation 
– Class IIa.
6. Asymptomatic  patients  with  preserved  LV  function  and  pulmonary 
hypertension (pulmonary artery systolic pressure > 50mm Hg at rest or > 60 
mm Hg with exercise) – Class IIa
7. Asymptomatic  patients  with  ejection  fraction  0.50 to  0.60  and end-systolic 
dimension < 45 mm and asymptomatic patients with ejection fraction > 0.60 
and end-systolic dimension  45 to 55 mm – Class IIa.
8. Patients  with  severe  LV dysfunction  (ejection  fraction  <  0.30  and/or  end-
systolic dimension > 55 mm) in whom chordal preservation is highly likely – 
Class IIa.
9. Asymptomatic patients with chronic MR with preserved LV function in whom 
mitral valve repair is highly like – Class IIb.
10. Patients with MVP and preserved LV function who have recurrent ventricular 
arrhythmias despite medical therapy – Class IIb.
11. Asymptomatic patients with preserved LV function in whom significant doubt 
about the feasibility of repair exists – Class III.
REVIEW OF LITERATURE 
History of valve surgery :-
  Cardiac valve repair or replacement under direct vision awaited the development 
of  the  heart-lung  machine.  With  the   contribution  by   John  Gibbon  to  the  the 
development of the heart-lung machine, valve replacement become feasible. The first 
successful prosthetic mitral valve replacement was done by Nina Braunwald in 1960.
(10)This was followed by  Starr and Edwards,   replacing the   mitral valve with a caged 
ball valve  in September 1960, from then problems of post operative low cardiac output, 
thromboembolism, anticoagulation related bleeding came to the fore.(11)
 Due to its improved flow dynamics  and decreased thromboembolic complications 
the first clinical trial with the St.Jude medical prosthesis was initiated in April 1979.This 
is a low profile bileaflet  tilting disc Valve constructed entirely (except for the sewing 
ring  made  of  polyester)   with  pyrolytic  carbon.  The  graphite  substrate  of  leaflet  is 
tungsten impregnated for radiopacity.(12)
Central  flow  design  offers  a  lower  transvalvular  gradient  ,  durable 
,thromboresistance, low incidence of valve related adverse events. Of the more than 70 
mechanical  valves  in  clinical  usage   the  St.Jude  medical  valve  has  been  the  most 
successful and has been the gold standard for mitral valve replacement(13,14,15,16,17) 
in all age groups, from infant to the elderly . (18,19,20,21,22,23)
According  to  Crawford  etal   the  immediate  operative  mortality  for  valve 
replacement may not be related to the type of prosthesis used (12).
Lim etal  reported from their study that  Carbomedics and St Jude valve had no 
significant difference in early & midterm clinical outcomes. The choice with respect to 
valve type can be based on other than patient outcomes.(24).
Eric  etal  also  confirmed,  no  significant  differences  exists  with   regard  to 
thromboembolic  and  hemorrhagic  complications  between  Carbomedics  &  St  jude 
prosthetic valves.(25)
 Camilleri etal in their study  concluded,  no significant difference exists between 
St. Jude Medical and Sorin Bicarbon valves over a 4-yr period of  follow-up with respect 
to morbidity, mortality and  event free survival rates (26).
Murday  etal  compared Starr Edwards and St. Jude prostheses in the aortic and 
mitral  positions.  They  found  no  differences  in  complication  rate  or   symptomatic 
improvement between the Starr Edwards and St. Jude valve prostheses in either aortic or 
mitral position. Left ventricular function had such a impact on long-term survival that it 
overwhelmed any differences  between different prosthetic valve designs.(27).
Ye-Ying Cen   etal  in their analysis of Carpentier-Edwards bio prosthesis  and 
St  Jude  mechanical  valve   found  ,  10-year  survival  was  not  statistically  different 
between the  two  but  factors predicting  adverse survival after mitral valve replacement 
were older age, lower ejection fraction, presence of class IV congestive heart failure, 
coronary artery disease, renal disease, smoking history, hypertension, combined valve 
surgery, and redo heart surgery. Choice of biologic or mechanical prosthesis does not 
significantly affect long-term patient survival after mitral valve replacement.(28).
Douglas  etal  from their study  with   St. Jude or porcine mitral valve replacement 
found no statistical differences in symptomatic improvement, mortality ,complications 
and  actuarial survival.(29)
According  to Ikonomidis  etal    valve  replacement  patients  do  not  survive  in 
parallel  to  normal  population.   Factors  influencing  the  operative  mortality  are  age, 
previous valve replacement,  cardiac function,  coronary artery disease   these factors 
influence on operative mortality than the type of valve prosthesis implanted. Late death 
is unrelated to prosthetic valve, and the factors influencing the long term outcome is 
higher NYHA class,  concominant CABG, increasing age. (14)
 De Santo etal  in  their  study with young rheumatic  women  identified    atrial 
fibrillation   as a risk factor for late mortality, whereas higher left ventricular ejection 
fraction at 12 months postoperative  proved to be a protective factor.(30).
Remadi etal  in their study  identified  age and sex  as  significant risk factors  for 
valve-related mortality and that higher age, female sex, higher NYHA class, and atrial 
fibrillation had  significant correlation with overall  higher mortality(15)
Fernandez  etal from their   study reported, that risk for   inhospital mortality 
included  older age, female gender , higher preoperative left ventricular end-diastolic 
pressure,  previous  cardiac  operation  ,  longer  aortic  crossclamp  time  ,  and  longer 
cardiopulmonary bypass time .  Risk factors for  late death included older  age,  lower 
preoperative ejection fraction , longer aortic crossclamp time, longer cardiopulmonary 
bypass time , previous cardiac operation, and higher preoperative functional class .(16)
According to Arom etal  thrombo embolic  events  may occur some times because 
of valve thrombosis, but in general  they arose  from adjacent part of sewing ring. The 
embolic incident can occur without evidence of associated valve dysfunction. (31)
Duncan etal  noted the factors  that   led  to thromboembolism were  enlarged 
cardiac chamber(S),  calcification in chamber walls or  annulus,  dysrhythmias  and 
techniques of operative implantation.(32)
Debétaz   etal   prognosticated the    Independent  preoperative risk factors   for 
embolism,  were  cardiac failure as an  indication for operation and history of prior 
systemic embolism (33)
Emery etal observed that  thromboembolism  is more common in the  immediate 
postoperative period and has a continuous hazard phase through out  the  life  of  the 
patient. Thromboembolism   is very high in early postoperative period in the face of 
newly implanted sewing ring which is a  nidus  for emboli production.(13)
De Santo etal observed that   Atrial fibrillation was significantly associated with a 
higher  incidence of thromboembolic events.(30)
 Remadi etal   found  valve replacement   patients had persistent  problem with 
anticoagulation  management even after 10 years follow up  which  alter the quality of 
life. Hence the recommendation for   mitral plasty techniques, whenever it is  technically 
feasible. Light anticoagulant treatment is now recommended for patients in sinus rhythm 
to decrease  the serious hemorrhagic complications.(15).
Emery etal    in their study observed that anticoagulation related hemorrhage is 
more common in the first  postoperative year. Patient related factors are important than 
valve  related  factors.  Hence  they   advised    the  target   INR  for   patients   to  be 
individualised  .(13)
Hering etal  in  their  study found out,   thromboembolism following AVR was 
significantly  lower  than  after  MVR.   Comparing  three  different  intensities  of  oral 
anticoagulation  in  valve replacement patients , they found out that the  incidence of 
thrombo embolism and bleeding complications was comparably low in all INR strata 
and  recommended   to    reevaluate  the intensity of anticoagulation in patients with the 
SJM valve.(34)
Lafci  etal   in their study with  bileaflet valve thrombosis, found out  majority of 
patients had  subtherapeutic anticoagulation  level leading to valve thrombosis and they 
presented in NYHA class IV symptoms clinically. (35)
Shapira  etal   from their  study  inferred  that  bileaflet  valves  have  delicate 
mechanism  and   may lead more easily to leaflet immobilization, even with a relatively 
small clot. (36)
Deviri etal from their  study  observed,  majority of the thrombus was at the hinge 
site, causing impairment of both leaflet motion.  Amount of thrombotic material needed 
to cause interruption of   leaflet motion in bileaflet valves is minimal, especially if it 
catches the hinges of the  valve. A small thrombus may even entrap the hinges of both 
leaflets(37)
Laplace  etal  noted higher incidence (about 10%) prosthetic valve thrombosis in 
early  postoperative   period   with  in  nine  days.  Pre  operative   atrial  fibrillation 
immediate postoperative impaired left ventricle ejection fraction  (<50%), and high dose 
protamine   plus inadequate postoperative  anticoagulation are implicated. Formation of 
thrombus   is   explained  by   Virchows   triad  -cardiac  surgery,   mechanical  valve, 
extracorporeal circulation   damages  the native tissues, while artificial surfaces alters 
the  rheology with stagnation of blood , reducing  the flow velocity.  A hypercoagulable 
state  exists  due  to  platelet  leucocyte  ,  and  coagulation  factor  activation,  fibrinogen 
maintaining  the   vicious  cycle.  Hence  in  their  study  they  advocated  the  need  for 
transesophageal echocardiogram in the immediate post operative period.(38).
Cowgill etal observed in their study that predominant cause of early  prosthetic 
valve endocarditis (<60 days ) is caused by  S.Epidermiditis,  followed by S.Aureus due 
to   perioperative   contamination.  Late  prosthetic  valve  endocarditis(  >60 days  )   is 
predominated  by Streptococcal infection.(39)
Arom etal    observed that the incidence of prosthetic valve  endocarditis  can be 
reduced  by prophylactic antibiotics prior to valve replacement, shorter operating time, 
and improved antibiotic prophylaxis for minor or invasive procedures.(31)
Wells etal observed patient in AF  had a lower survival  rate compared to sinus 
rhythm patients. The onset of AF is an indicator  of severity and chronicity of disease 
due to its association with poor LV  function.  Early  surgery after the onset of AF  has 
its  benefits . Lower survival  was seen in patients who persist  in AF in post operative 
period. Left atrial size were significantly larger in patients who were in atrial fibrillation 
even after surgery.(40)
Mehta  etal reported that  in patients  in sinus rhythm,  the prevalence of left  atrial 
clot was  0% in mitral regurgitation    and   14.3% in patients with mitral stenosis.(41)
Diker  etal   in their study reported, AF has been found in 40% of cases with 
mitral stenosis and 25% of cases with mitral regurgitation.(42)
Falk  etal  in their   study reported  Atrial fibrillation is responsible  for more than 
85% of systemic thromboembolism from the heart.(43)
 Kannel  etal from their study confirmed that when associated with mitral valve 
disease,  AF  has  the    highest  stroke  risk   about  seventeen  times  greater  than  in 
unaffected controls. In comparison, in patients with nonvalvular heart disease, the risk is 
increased five-fold.(44)
Jorgensen   etal   reported  Stroke  in  patients  with  AF is  associated  with  70% 
increased    mortality  and  very  poor  neurological  and  functional  outcome.   The 
recurrence rate in the first year after the initial stroke varies between 13% and 32%.(45)
Morris reported  that  Lifetime stroke recurrence rates, especially for patients with 
AF associated  with mitral valve disease, may be as high as 30%–75%.(46)
Shuhaibera etal noted in their  meta- analysis  of  29 published studies, a  strong 
evidence at 30 day and overall survival favouring   mitral valve repair  in rheumatic 
mitral  valve disease. The risk of thrombo embolism is also lower in Repair group.(47)
Carpentier   etal   had  shown  good  long  term  results  with  repair  of   young 
Rheumatic  patients  with   mitral  insufficiency.  The  out  come  is  superior  to  valve 
replacement procedures. Repair had a low hospital mortality rate and an acceptable rate 
of  reoperation  with  minimal  risk  of  thromboembolic  events  in  repair  compared  to 
replacement.(48)
According to Chowdhury etal   total chordal preservation is possible in the large 
majority of rheumatic patients and this helps to  preserve  left ventricular function .(49)
Miller etal   described  that  preservation of all or part of the posterior leaflet and 
its chordae does not  interfere with prosthetic valve function  and it helps to reduces  the 
risk of ventricular rupture  and  enhances the survival after  mitral valve replacement.
(50)
Jun Zhang etal   reported that   mortality  following LV rupture in mitral  valve 
replacement  was   61.5%   and   advised   careful  removal  of  diseased  valve  , 
decalcification,  and  prosthesis  selection  should   minimize  the  incidence  of  left 
ventricular rupture. Immediate diagnosis and urgent surgical intervention are   crucial 
for successful out come.(51)
Hillman etal  reported that young adults (  < 21 years ) with  rheumatic heart 
disease  had good result with Mitral repair surgery in  that it allows annular growth  with 
good long term   functional result. (52)
Yau  etal  described that Mechanical valves minimize reoperation rate  but at the 
cost  of   limiting  the   survival  and  increases   the   thromboembolic  complications. 
Patients   undergoing  valve  repair  had  improved  late   survival  independent  of  their 
preoperative  characteristics.  Rheumatic  mitral  valves  should  be  repaired  when 
technically  feasible, accepting a  small risk of reoperation, to maximize survival and 
reduce morbidity  (53) 
AIMS AND OBJECTIVES
1) To  study  the  complications  associated  with  Mechanical  Mitral  valve 
replacement.
2) To Study  the  influence   of  AF on outcome following Mitral  valve replacement.
MATERIALS AND METHODS
This prospective  study  was  conducted between  June 2005 to December  2006 
on 179  consecutive  patients  undergoing valve replacement with  St. Jude prosthetic 
Mitral valve. Valve lesion other than tricuspid valve was not included  in this  study. 
Similarly ischaemic  mitral  regurgitation  was not included. Previous open heart surgery 
patients  were   not   included in this  study.  St.Jude  bileaflet  low profile  prosthetic 
valve   Masters series MJ 501 with  standard polyester cuff was used in all patients. 
Male patients 40 years and above and female patients 45 years and above without  risk 
factor for ischemic heart disease  and  those patients   who  are at high risk  for ischemic 
heart disease were subjected to coronary angiogram  pre operatively.
Operative technique:-
Surgery  was  conducted  with  a  midline  sternotomy  incision,   standard 
cardiopulmonary bypass  with   Aortic ,  bicaval   cannulation, core was cooled to 28*C. 
Heart was arrested with hyperkalemic blood cardioplegia, with topical ice slush being 
used to cool myocardial temperature .Left atrium was opened parallel to the interatrial 
groove  in  those  patients  who  have  isolated  mitral  pathology  .In  ASD,  Tricuspid 
regurgitation,  LA  myxoma  patients  Right  atrium  was  also  opened  .   Surgery  was 
conducted after inspecting the mitral  valve  for suitability for chordal preservation . 
St.Jude   prosthetic  mitral  valve  MJ501  masters  series  was used  in  all  patients  and 
suturing was done with 2 0 Ethibond sutures  with plegets using a  horizontal interrupted 
mattress  technique.  Continuous    suture  technique  for   those   annulus  not  severly 
diseased  or  calcified  was  employed too  .The   valve   was   placed in   intra  annular 
position.
Patients were ventilated electively  and  ionotropes used  depending up on the 
hemodynamic  needs. On first post operative day  heparin was given along with oral 
anticoagulant (Acenocoumarol) and continued until the target INR of 2.5 to 3.0 reached, 
then  heparin  stopped.  Anticoagulant   dose   was  regulated  by  surgeons  during 
hospitalization and during subsequent follow up  in the outpatient  department. Patients 
came for regular follow up every 15 days for drug collection and for clinical assessment. 
In those  patients who were  symptomatic or clinical suspicion of deterioration were 
present subjected to  detailed evaluation. 75% of the patients were  still in  follow up .
Age group (in yrs)
1 .6
41 22.9
64 35.8
45 25.1
23 12.8
5 2.8
179 100.0
<10 yrs
11-20 yrs
21-30 yrs
31-40 yrs
41-50 yrs
51-60 yrs
Total
Frequency Percent
Sex
109 60.9
70 39.1
179 100.0
Female
Male
Total
Frequency Percent
TABLES
Table : 1
Table : 2
Diagnosis
46 25.7
20 11.2
84 46.9
29 16.2
179 100.0
MR
MRS
MS
MS/MR
Total
Frequency Percent
Table : 3
Etiology
Frequency Percent
Congenital 1 0.6
Degenarative 5 2.8
Rheumatic 173 96.6
Total 179 100
Table : 4
Co morbidity-details
2 5.4
5 13.5
3 8.1
2 5.4
21 56.8
1 2.7
3 8.1
37 100.0
ACUTE MR
ASD
CAD
INF. ENDOCARDITIS
LA CLOT
LAMYXOMA
TR -SEV
Total
Frequency Percent
Previous Sx
22 12.3
157 87.7
179 100.0
CMC
NIL
Total
Frequency Percent
Table : 5
Table : 6
NYHA-Preop
4 2.2
142 79.3
31 17.3
2 1.1
179 100.0
C2
C3
C4
C5
Total
Frequency Percent
AF/NSR-Preop
70 39.1
109 60.9
179 100.0
AF
NSR
Total
Frequency Percent
Table : 7
Table : 8
Table : 9
Elective/Emergency
176 98.3
3 1.7
179 100.0
ELE
EMER
Total
Frequency Percent
EF% -Pre op
170 95.0
9 5.0
179 100.0
50 and above
30-49
Total
Frequency Percent
Table : 10
Table : 11
Procedures
Procedures Frequency Percent
CMC + MVR 2 1.1
ISOLATED MVR 144 80.4
MVR+ASD 5 2.8
MVR+CABG 3 1.7
MVR+DEVEGA 3 1.7
MVR+LAMyxoma excision 1 0.6
MVR+LA.CLOT removal 21 11.7
Total 179 100.0
Table : 12
Classical / Chordal Preservation
Procedure Frequency Percent
Chordal 83 46.4
Classsical 96 53.6
Total 179 100.0
Table : 13
valve size
Size 
mm
Frequency Percent
25 66 36.9
27 92 51.4
29 21 11.7
Total 179 100.0
Table : 14
Post op NSR / AF:
Frequency Percent
AF 67 37.4
NSR 110 61.5
EF% -Post op
129 77.7
37 22.3
166 100.0
50 and above
30-49
Total
Frequency Percent
EF% -Pre op * EF% -Post op Crosstabulation (AMONG CLASSICAL
REPLACEMENT GROUP)
49 31 80
61.3% 38.8%
3 3
100.0%
49 34 83
50 and above
35-49
EF%-Pre
op
Total
50 and above 35-49
EF%-Post op
Total
Pacing 2 1.1
Total 179 100.0
Table : 15
Table : 16
EF% -Pre op * EF% -Post op Crosstabulation (AMONG CHORDAL
PRESERVATION GROUP)
78 3 81
96.3% 3.7%
2 2
100.0%
80 3 83
50 and above
35-49
EF%-Pre
op
Total
50 and above 35-49
EF%-Post op
Total
Table : 17
Complications
141 78.8
6 3.4
2 1.1
2 1.1
4 2.2
8 4.5
2 1.1
1 .6
1 .6
2 1.1
1 .6
4 2.2
1 .6
2 1.1
1 .6
1 .6
179 100.0
No complication
Valve thrombosis
Thrombo- Embolism
Prosthetic valve
endocarditis
Bleeding event
Myocardial failure-LCO
DecubitusUlcer
Haematuria
LA Appendage tear
LV rupture
Mediastinitis
Superficial wound
infection
Ventricular arrythmia
Bleeding reexploration
CCF
intraopCoagulation failure
Total
Frequency Percent
Table : 18
                                                                   
Table : 19
NYHA-Post op
14 7.8
19 10.6
117 65.4
28 15.6
1 .6
179 100.0
 
C1
C2
C3
C4
Total
Frequency Percent
Table : 20
Table : 21
Complications (AMONG 'NSR' PATIENTS)
94 86.2
2 1.8
2 1.8
3 2.8
1 .9
1 .9
1 .9
1 .9
3 2.8
1 .9
109 100.0
No complication
Embolism
Prosthetic valve
endocarditis
Bleeding event
Myocardial failure-LCO
Ulcer
Haematuria
Mediastinitis
Superficial wound
infection
Ventricular arrythmia
Total
Frequency Percent
Complications (AMONG 'AF' PATIENTS)
47 67.1
6 8.6
1 1.4
7 10.0
1 1.4
1 1.4
2 2.9
1 1.4
2 2.9
1 1.4
1 1.4
70 100.0
No complication
Valve thrombosis
Bleeding event
Myocardial failure-LCO
Ulcer
LA Appendage tear
LV rupture
Superficial wound
infection
Bleeding reexploration
CCF`
Coagulation failure
Total
Frequency Percent
Table : 22
Cause of death
Cause of death Frequency Percent
Valve thrombosis 3 1.7
Myocardial failure 8 4.5
Bleeding- coagulation failure 1 0.6
Prosthetic valve endocarditis 2 1.1
LV rupture 2 1.1
LA appendage tear 1 0.6
Ventricular arrythymia 1 0.6
Mediastinits-strenal infection 1 0.6
Total 19 10.8
OBSERVATION 
Of these 179  patient,  operated  with St.Jude  prosthetic mechanical   mitral valve 
replacement,   between  June  2005 to  December   2006  isolated MVR was done in 
144(80.4%).When LA clot   removal   was combined with MVR  procedure it accounts 
to 165(92.1%). Depending up on the  severity  of subvalvuar  lesion, classical or chordal 
preservation  was done. The chordal preservation could be total (Anterior and posterior 
leaflet ) or partial ( Posterior  alone). 
Aortic cross clamp time ranged  from minimum of 38 min  to  maximum  of 110 
min  and  Cardio pulmonary bypass time ranged from minimum  of  52min  to maximum 
of 140 min.  
Table 1: AGE DISTRIBUTION
Age ranged from 8 to 59  years. With mean age of  29.31+/-10.75. And median 
age of  27years.   
Table 2: SEX DISTRIBUTION
There  were  109(60.9%)  females  and  70(39.1%)  were   males,  with  female 
predominance.
Table 3: ETIOLOGY
Rheumatic  heart  disease  was  the  predominant  contributor  in  this  study  with 
173(96.6%), followed by degenerative 5(2.8%) and one case of congenital cleft  mitral 
leading to regurgitation (6%).
Table 4: DIAGNOSIS
Mitral  stenosis  was  the  predominant  lesion  84(46.9%),   followed  by   mitral 
regurgitation   46(25.7%).  Combined  lesion  accounted  for  29(16.2%)   and   Mitral 
restenosis subjected to MVR  was 20(11.2%).
Table 5: CO MORBID CONDITIONS 
        LA clot was the major associated comorbid  condition which accounted for 21 
(56.8%) for which Clot removal with concomitant  ligation of Left Atrial Appendage 
done. 
ASD were   Five (13.5%).  Three patients had undergone single vessel    Coronary 
artery disease (8.1%). Three patients  had Severe Tricuspid  Regurgitation  (8.1%).  Two 
patient presented with  infective endocarditis (5.4%) and another one person had a LA 
Myxoma (2.7%). 
Table 6: PREVIOUS SURGERY
              Closed  Mitral  Commissurotomy were done in 22 (12.3%) of patients. The 
prime indication now for  re operation is severe mitral restenosis. 
Table 7: ELECTIVE AND EMERGENCY  MVR
Out of 179 patient only  three(1.7%) emergency surgery undertaken. Of  which 
two(1.12%)  patients   were  post  closed  mitral  commissurtomy in cardiogenic  shock 
hence MVR done in same sitting. One patient who had LA myxoma was also taken as 
an emergency. Remaining 176(98.3%) of patients were taken  electively.
Table 8: PREOP NYHA
Patients  presented  commonly  with   class  3  symptoms  142(79.3%),  and   31 
patients were in class 4 (17.3%). Two patients post closed mitral commissurotomy were 
in Class   5 (1.1%). Combined class 3 and 4 presentation accounted 173(96.6%).
Table 9: PRE OPERATIVE  RHYTHM - NSR /  AF
Majority of the patients were in NSR 109(60.9%) & AF accounted for 70(39.1%).
Table  10: PRE. OPERATIVE  EJECTION FRACTION %
About 170(95%) of patients  had Ejection Fraction 50 %  and above. Only nine 
(5%) were between 30 – 49 %  of Ejection Fraction.
Table 11:PROCEDURES
Isolated MVR  was done in 144 (80.4%), when combined with LA Clot removal it 
accounted  165 (92.1%). LA clot was removed with concomitant  ligation of Left Atrial 
Appendage   in  these  patients.   Five  (2.8%)  ASD  Patients   had,  along  with  valve 
replacement ASD  Pericardial patch closure .Three(1.7%)  patients had undergone single 
vessel    CABG   for   Coronary artery disease.   Three(1.7%)  patients who had Severe 
Tricuspid  Regurgitation undergone MVR with  DEVEGA Annuloplasty . One person 
had a LA Myxoma  excision (0.6%) , combined with  valve replacement. Two(1.1%) 
patients  were post closed mitral commissurtomy in cardiogenic shock hence MVR done 
in same sitting.
TABLE 12  :CLASSICAL / CHORDAL PRESERVATION
Out   of  179  patients   96(  53.6%)  had  Classical  MVR   where  all  chordal 
attachment   was  excised  before  valve  replacement.  And  83(46.4%)  had  chordal 
preservation either partial or total.
TABLE 13: VALVE SIZE
In view of majority  of  stenotic lesion  27mm St.Jude valve was  maximum used 
which accounts   for 92(51.4%). This is followed by 25 mm valve 66(36.9 %). 
TABLE 14: AF / NSR POST OPERATIVEPERIOD
The commonest post operative rhythm is NSR 110(61.5%)  and AF accounted for 
67(37.4%).  Two  patients  who  were  in  junctional  rhythm  and  bradycardia   were 
supported with Epicardial  Pacing both of them who had LV  Rupture.
TABLE 15 :POST OPERATIVE EJECTION FRACTION % 
In  the immediate post operative period   pre  discharge Echo evaluation  showed 
129( 77.7%)  were  having ejection fraction 50 % and  above.  And  37(22.3%) of the 
patients were  having EF% between 30-49%. This drop in  EF% could be explained by 
majority of  the Procedure  were Classical in view of agglutinated, fibrotic chordae , 
papillary muscles &  preservation  in this cases were difficult.
TABLE 16: EF%-PREOP &EF%-POST OP CROSSTABULATION- 
CLASSICAL GROUP
This comparison  was done on those patients  who had  undergone classical repair 
and alive.
Of  the total 83 patients who are alive, preoperatively  80  patients  had  EF 50% 
and  above and  3 patients  had EF between  35-49%.  Out of  these 80 patients who had 
preop EF 50  & above , only 49 (61.3%) maintained their preop EF of 50 & above. And 
31(38.3%)  patients had EF  dropped to 35 – 49%. And those  three patients who  had 
pre op Moderate LV Dysfunction  EF (35-49) %  did not show any improvement in the 
post op.
TABLE 17: EF-PREOP & EF% - POST OP CROSSTABULATION- CHORDAL 
PRESERVATION  GROUP
This comparison  was done on those patients  who had  undergone Chordal  repair 
and alive. Of  the total 83 patients who were alive, preoperatively  81  patients  had EF 
in 50% and  above and  2 patients  had EF between  35-49%.     Out of these  81 patients 
who had preop EF 50  & above,  78 (96.3%) maintained their preop EF of 50 & above. 
And 3(3.7%)  patients had EF  dropped to 35 – 49%.  And those  two patients who  had 
pre op moderate LV Dysfunction  EF (35-49) %   showed improvement in the post op.
TABLE18 : POST OP  NYHA
Majority  of  the  patients   had  a  definitive  symptomatic  improvement  and 117 
(65.4%) were in NYHA  class 2 and 28 (15.6%) were in  NYHA class 3 respectively. 
About   19 (  10.6%) were in NYHA  class  1.    And  one (  0.6%).   patient  was in 
congestive failure in class 4.
TABLE 19 : COMPLICATIONS 
Commonest complication  post cardiac surgery here was myocardial failure with 
low cardiac output 8(4.5%), all the patient died in postoperative period. Next in the line 
was valve thrombosis 6(3.4%) of this ,3(1.7%)  patients died. Two (1.1%) patients had 
thrombo emboli , both had diminished right vision and blindness. Another Two (1.1%) 
had prosthetic valve endocarditis. LV Rupture  was seen in two (1.1%) and two (1.1%) 
of patient had to under go re exploration for increased inter costal drainage. One (0.6%) 
died  of  sudden cardiac arrest  due to  ventricular  arrhythmia.  Other  than   the  wound 
infection , transient elevation of LFT in two patients  in  the immediate post bypass 
period settled  on its own. 
TABLE 20 : COMPLICATION  AMONG ‘NSR’ PATIENTS 
Majority of   sinus rhythm patient had no   complications 94(86.2%). Three patients had 
superficial wound infection(2.8%) and two patients had thromboembolism (1.8%) and 
another  two  patients  had  prosthetic  valve  endocarditis  (1.8%).  one  patient  had 
myocardial failure and low cardiac output syndrome(0.9%), and another one patient died 
of mediastinitis(0.9%).Ventricular  arrythmia occured in one patient  in post  operative 
period and died(0.9%). Bleeding events occured in three (2.8%) patients were of trivial 
in nature, which was managed  conservatively. 
TABLE 21 : COMPLICATIONS AMONG  AF PATIENTS :
Majority of the patients with  AF had died of myocardial failure and low cardiac output 
syndrome 7(10%), followed by valve thrombosis in  six (8.6%)patients, two patients had 
LVrupture  intra operatively and one patient  had Left  atrial  appendage tear  and died 
intraoperatively.  Two patients  were  explored  for  increased  intercostal  drainage.  One 
patient died intraoperatively, due to coagulation failure. Decubitus ulcer and superficial 
skin wound infection occured in one patient each.  one patient was in congestive cardiac 
failure  postoperatively. one patient had major bleeding episode and was admitted to the 
hospital . About 47(67.1%) of patients had no complications.
TABLE 22 : CAUSE OF DEATH
The leading cause of death  in this study  was myocardial failure with Low cardiac 
output syndrome 8(4.5%). This was followed by valve thrombosis 3(1.7%). Prosthetic 
valve endocarditis  & LV Rupture  caused two(1.1%) deaths each.  Mediastinitis, LA 
Appendage tear, coagulation failure ,bleeding  and Arrythmia all contributed 1(0.6%) 
each.Over all mortality  due to all causes  was 19 (10.8%). And operative mortality  was 
14 (7.8%).
DISCUSSION 
The  patients  age  ranged  between  8-59  in   this  series,  with  a  mean  age  of 
29.31+/-10.75 and a  median  0f  27  years,   comparable  to  Choudhary  etal   study  of 
rheumatic population with mean age was 22.8 +/- 11.3 years  with range, 2 to 70 years.
(54)
In  Emery,etal study (13)  the  mean age  was   60+/-12.8    which was on  the 
higher side, which  implies that  Rheumatic etiology is a major factor in Indian scenario. 
Kirklin described an accelerated form of RHD  in certain ethnic group with early onset 
of manifestation due to prior severe attack of RF (55).  The  majority  of patients in this 
study were  females with Mitral stenosis being the major lesion   caused by Rheumatic 
etiology.
According to Ikonomidis etal study  60% were   females affected by Rheumatic 
etiology and  Mitral  regurgitation  being the  major  presentation .(14)
  In   Demirag etal   study,  58.7% were females.  The reason for  operation was 
combined  mitral stenosis plus regurgitation in 36.96%  and   etiology  being  acute 
rheumatic fever in 75.36%. (17).
          The predominant comorbidity in this study was  LA clot. Khalaf  etal  in their study concluded 
LA clot  being predictor of  inhospital mortality in MVR . Since large clot  adherent to the left atrium & 
appendage   takes  longer  time for removal  which  increases the ischemic time, cardio pulmonary 
bypass time at the same time predisposing to  injury to the  friable  left atrial wall. Friable  materials 
may  embolise in  the immediate  post operative period.(56)
Coronary artery disease is an important  long term  predictor of post operative 
outcome. In this  series  out of three coronary artery disease patients operated one patient 
with diabetes died  because of   mediastinitis and sternal infection,  another patient died 
of myocardial failure with low cardiac output in the  post operative period.
According to   Losanoff etal   infection of median sternotomy  wound  leads to 
mortality rate between 14 and 47%   secondary   to  underlying mediastinitis  .Risk 
factors  for  sternal  wound  dehiscence  includes  diabetes  mellitus,  chronic obstructive 
airway disease, obesity, smoking, Prolonged bypass time, excessive bone wax, too much 
use of diathermy, all of which can  inhibit wound healing,  with increased   transfusions , 
reexploration, prolonged postoperative ventilation and longer stay in the ICU  leading to 
increased  dehisence.(57).
Herlitz etal    proposed  mitral valve surgery in combination with CABG was 
independently associated with increased  death and  higher rehospitalization.(58)
 According to Ashraf  etal   higher inhospital mortality for combined CABG and MVR patients 
depends on  NYHA functional class  left ventricular global wall motion score (increased scores 
indicating impaired function)  and prolonged cross-clamp time.(59)
Emergency  MVR  was  done   in  two Acute  Mitral  regurgitation  patients  post 
closed mitral  commissurotomy ,  the patients  were in  low cardiac out  put  and acute 
pulmonary edema. Immediately on  the table conversion to MVR  was done, there was 
no  pre operative waiting period for these patients, of these two patient one died in the 
post operative period due to  ventricular arrythymia.
Combined procedure carries higher mortality compared to isolated procedure.
Ibrahim  etal   in  their   study   identified   age,  previous cardiac operations, 
diabetes  mellitus,  extent  of  coronary  artery  disease,  preoperative  NYHA  class,  and 
additional procedures  as   independent prognostic factors for overall survival. (18)
Previous cardiac surgery was a  predictor  of  inhospital mortality. In our series 
out  of  total  mortality  of  19  patients  six  patients   died   intraoperatively  or  in  the 
immediate  post operative    period  due  to redo Mitral surgery.   Dense adhesions of 
previous surgery prolongs the intraoperative time, ischeamic time and cardiopulmonary 
bypass time, high risk for LV  Rupture and  LA Appendage damage. 
Rutledge  etal   in  their  series  found  that  patients  undergoing   Mitral  valve 
replacement  after  closed  mitral commissurotomy   had  a  Perioperative   mortality  of 
13%.(60)
Sampath  Kumar   etal  in  their  experience  with  redo mitral  surgery  had  early 
mortality of  5.64%  with  hemorrhage  and low cardiac output being the major causes of 
death . On follow-up they found no late deaths in the valve repair group.(61)
Treasure  etal  enumerated  the  causes  for  LVdisruption   in  MVR  as,  heavily 
calcified annulus ,too large a  valve implantataion, strut near A-V groove  and  previous 
cardiac surgery. (62)
Compared  to  preoperative functional status the  post operative cardiac status 
improved  significantly.  In the Pre operative period  96.6%  were in NYHA class 3 or 4, 
and in the post operative period  76% were  in class 1 or 2.
 Majority of the patient in  this series presented very late with higher NYHA  3 or 4 class. 
Various studies have clearly pointed  out the need to intervene early, before  patient moves to higher 
NYHA class  and LV deterioration.. 
Lee etal    reported from their  study that,  Preoperative NYHA class  III  or  IV 
symptoms and left ventricular impairment were independent risk factors for death and 
myocardial failure. Early mortality was lower in the valve  repair and MVR-subvalvular 
preservation  group  compared to  Classical MVR group.  Since myocardial failure is the 
main  cause  of  death in  mitral  valve  surgery  ,  subvalvular  preservation reduced  the 
severity  of  myocardial  failure rather  than preventing it  .  Not only will  Conservative 
surgery   optimizes   the  outcome   but   the  early  surgery   before  severely  limiting 
symptoms or LV impairment  gives better outcome.(63).
 In this study , patients  who had undergone chordae preservation majority  maintained their 
post operative EF% in the normal range.
Chronic AF is not a benign rhythm in the long term. In this study all the post 
operative valve thrombosis patients were in AF preoperatively Except for one, all the 
others were in fast ventricular response at time of admission with thrombosed valve. 
Valve thrombosis patients presented from  two to six  months after  post MVR. At the 
time of admission all six were in sub therapeutic level of anticoagulation. One patient 
presented   clinically with  stroke ,  one with TIA which was evaluated and diagnosed. 
Remaining patients presented in NYHA class 4 symptoms. One patient died of stroke , 
other two patients died of cardiac failure. 
Deviri  etal  in their  study with valve thrombosis patients found that the time 
interval between valve replacement and obstruction ranged from 6 weeks to 13 years 
(median 4 years). Of 63%  patients in whom coagulation profile was  available at the 
time of obstruction, 70% were receiving inadequate anticoagulant. About  63% of the 
patient were  in New York Heart Association functional class IV.(37)
Lafci etal  from their study concluded that  subtherapeutic anticoagulation level 
was  the  major  etiologic  factor  involved  in  the  pathogenesis  of  valve  Thrombosis  . 
Thrombosis occurred in the mitral position in  (78%), compared to  aortic position in 
(22%) in their series. The mean duration from valve replacement to valve thrombosis 
was 48.3 +/- 15.4 months. The majority of patients presented with poor functional status 
(56% in NYHA class IV) and poor anticoagulation (INR < or = 2 in 72% of cases) (35).
Of  the two thromboembolic episode and fatal loss of vision one patient presented 
in the early post operative period, probable cause would  be  particulate debris or air 
emboli. Other patient  at time of admission had low INR level.
One patient  presented in this series with anticoagulant  related hemorrhage  as 
gastrointestinal bleed which required admission and blood and factors transfusion. Other 
presented with minor bleeding event  required anticoagulant modification strategies.
Remadi etal  in their series had problem maintaining  target  INR, hence  they 
advocated for a lighter  anticoagulant strategy for patients in sinus rhythm with  self 
monitoring of INR like in  blood glucose monitoring in home.  (15).
In this series two patients had prosthetic valve endocarditis ,  microbial etiology in 
one being affected  by candida and other being affected by acineto bacter baumannii. 
Both    patients  had  blood  culture  positive  for  organism  at    different  occasions. 
Acinetobacter baumannii infected  patient  presented  after  two  months  with  sternal 
infection.
 According to  AliIlgin  etal   Acinetobacter is  a highly resistant microorganism, 
commonly isolated in intensive and post-operative care units. It may constitute one  of 
the several causes  of early prosthetic valve endocarditis.  A diffuse, red maculopapular 
rash may be encountered in patients with Acinetobacter endocarditis.(64)
Of  the overall mortality of 19 patients , 14 (73.68 %)of them  were in AF and 
5(26%) in NSR.
SUMMARY
Between June 2005 and December 2006 , 179 St Jude mechanical mitral valves 
were implanted. Age ranged  from 8 to 59years, mean age 29.31+/-10.75 with median of 
27 years. Majority being female 109(60.9%) with Rheumatic heart disease 173(96.6%) 
being  the commonest etiology with Mitral  stenosis 84(46.9%) as the major lesion . 
overall mortality was 19(10.8%) and in hospital mortality was 14(7.8%) and about 75% 
of the patients were still in regular follow up. LA clot 21(56.8%)  being the major co 
-morbid condition  followed by ASD 5(13.5%) and TR & CAD 3(8.1%) constituted 
each. One patient had LA Myxoma 1(2.7%);  Mitral restenosis 20(11.2%). NYHA 
class  preoperatively  3  and  4  combined173(96.6%).  Most  patients  were  in 
NSR109(60.9%) and AF (39.1%) with majority having  LVEF  fifty  and  above 
170(95%).  Isolated  MVR  144(80.4%)  being  the  commonest  procedure  ,  CABG  & 
Devega annuloplasty  being 3 (1.7%) each. Classical procedure MVR 96(53.6%) and 
chordal preservation  in 83(46.4%)only. Post operatively out of 80 Pre. op normal EF 
patients  only49(61.3%)  had  normal  EF  in  the  classical  group.  And  in  the  chordal 
preservation group out of 81 pre op. normal  EF  patients  78(96.3%)  had normal EF 
postoperatively  .  Most   of  valve  replacement  patients    had  definitive  symptomatic 
improvement in NYHA class, majority  were in NYHA 1 and  2 combined 136(76%). 
Majority   of  the patient  were in  Sinus Rhythm 110(61.5%) ,  AF  67(37.4%). 
There was no structural valve failure, no paravalvular leak or valve related hemolysis. 
There  were  6  (3.4%)  valve  thrombosis;  prosthetic  valve  endocarditis  2(1.1%); 
anticoagulant  related  hemorrhage  4(2.2%);  thromboembolism  2(1.1%);  myocardial 
failure 8(4.5%); LV rupture 2(1.1%).
High NYHA Class , AF, associated CAD, Redo mitral surgery were  significant 
risk  factors for inhospital mortality and the presence of  AF  was a significant risk factor 
for  increased mortality and morbidity on follow up.
CONCLUSION
Mitral  valve  replacement  cannot  normalize  the  life  expectancy.  Valve 
replacement has its own  limitations. Population coming for mitral valve replacement are 
under  privileged  ,  and   they    lack  financial  backup  to  manage  the  post  valve 
replacement  sequelae.   Valve replacement  is  not  the end of  the disease but   a  new 
beginning  of  a chronic disease lying  dormant ,  ready to blow off at  any  time, given a 
chance.   The  best  way to  address    this  issue  is  to  stress  the   importance  of  mass 
education, school health education, strict implementation of secondary prophylaxis and 
an  early  clinical    trial  for   vaccines   for  rheumatic  fever.  In  failed  cases  earlier 
intervention should be done and not to wait until the heart fails, or AF sets in. Timely 
intervention   when the valve is suitable for conservative procedures  and  to promote 
valve  sparing surgery  as much as possible, there by avoiding the prosthetic valve. In 
the established cases  conservative surgery in the form of chordal preservation  should 
be  done with antiarrythymic surgery  whenever  possible.
 A diligent  search  should be made to find  a  valve substitute that  lacks the 
problems ,  presently   available   prosthesis have. 
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